Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$4.73 USD
+0.06 (1.28%)
Updated May 16, 2024 04:00 PM ET
After-Market: $4.72 -0.01 (-0.21%) 7:24 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
INZY 4.73 +0.06(1.28%)
Will INZY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for INZY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INZY
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Why Earnings Season Could Be Great for Inozyme (INZY)
INZY: What are Zacks experts saying now?
Zacks Private Portfolio Services
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
Other News for INZY
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)
Buy Rating on Inozyme Pharma Supported by Advancements in Lead Program and Promising Market Opportunities